Cellectar Biosciences, Inc. CLRB

CLRB Company Overview

Cellectar Biosciences, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on the development of targeted radiotherapeutics and phospholipid drug conjugate (PDC) technologies for the treatment of cancer. The company operates primarily within the oncology and radiopharmaceutical industries, with a strategic emphasis on hematologic malignancies and difficult-to-treat solid tumors. Its core platform is designed to selectively deliver therapeutic payloads directly to cancer cells while minimizing exposure to healthy tissue.

The company’s principal product candidate is iopofosine I 131, a targeted radiotherapeutic utilizing the company’s proprietary PDC delivery platform. Cellectar has concentrated much of its development activity on indications such as Waldenström macroglobulinemia, multiple myeloma, and central nervous system lymphomas. The company traces its origins to Novelos Therapeutics, Inc., before rebranding as Cellectar Biosciences in 2011 to reflect its strategic transition toward phospholipid ether analog-based oncology therapeutics and radiopharmaceutical development.